Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003387 · ClinicalTrials.gov registry record · Phase 3
Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery
A Phase 3 study of Lung Cancer, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 366
- Enrollment target
- 20
- Study locations
NCT00003387 is a Phase 3 study of Lung Cancer that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 366 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT00003387, a Phase 3 study of Lung Cancer, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 366 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether giving chemotherapy before combined chemotherapy and radiation therapy is more effective than combined chemotherapy and radiation therapy alone in treating patients with non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of carboplatin and paclitaxel followed by radiation therapy and chemotherapy with radiation therapy and chemotherapy alone in treating patients with stage III non-small cell lung cancer that cannot be removed during surgery.
Conditions Studied
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- RADIATION radiation therapy
- DRUG chemotherapy
Study Locations (20)
California
- University of California San Diego Cancer Center - La Jolla
- Veterans Affairs Medical Center - San Francisco - San Francisco
- UCSF Cancer Center and Cancer Research Institute - San Francisco
Illinois
- University of Illinois at Chicago Health Sciences Center - Chicago
- Veterans Affairs Medical Center - Chicago (Westside Hospital) - Chicago
- University of Chicago Cancer Research Center - Chicago
District of Columbia
- Howard University Cancer Center - Washington D.C.
- Walter Reed Army Medical Center - Washington D.C.
Iowa
- Hematology Oncology Associates of the Quad Cities - Bettendorf
- Holden Comprehensive Cancer Center at The University of Iowa - Iowa City
Massachusetts
- Dana-Farber Cancer Institute - Boston
- University of Massachusetts Memorial Medical Center - Worcester
Missouri
- Veterans Affairs Medical Center - Columbia (Truman Memorial) - Columbia
- Ellis Fischel Cancer Center - Columbia - Columbia
Alabama
- Veterans Affairs Medical Center - Birmingham - Birmingham
Delaware
- CCOP - Christiana Care Health Services - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 366 participants |
| Start Date | 1998-07 |
| Est. Completion | 2009-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003387
The ClinicalTrials.gov registry entry for NCT00003387 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 366 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (61% lower). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which carboplatin is the first listed.
NCT00003387 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Illinois, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT00003387 about?
NCT00003387 is a clinical study titled "Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether giving chemotherapy before combined chemotherapy and radiation therapy is more effectiv...
What is the current status of trial NCT00003387?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 366 participants. The study started on 1998-07. Estimated completion is 2009-04.
What conditions does trial NCT00003387 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT00003387?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), radiation therapy (RADIATION), chemotherapy (DRUG).
Who is sponsoring clinical trial NCT00003387?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003387 being conducted?
This trial has 20 study locations across Alabama, California, Delaware, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
ACTIVE NOT RECRUITING · Phase 3
-
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
COMPLETED · Phase 3
-
Gemcitabine and Carboplatin Followed By Docetaxel in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.